CUBICIN RF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CUBICIN RF (CUBICIN RF).
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and disruption of membrane potential, leading to cell death.
| Metabolism | Largely excreted unchanged via kidneys; minimal hepatic metabolism (oxidative metabolites) |
| Excretion | Renal excretion: approximately 80% of the dose as unchanged drug; biliary/fecal elimination: minor (<5%). |
| Half-life | Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | 90-93% bound to human plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution (Vd): 0.1-0.2 L/kg, indicating limited tissue distribution; predominantly in extracellular fluid. |
| Bioavailability | Intravenous: 100% (only route of administration); no oral formulation available. |
| Onset of Action | Intravenous: rapid, within minutes; complete bactericidal activity achieved within 1-2 hours post-infusion. |
| Duration of Action | Duration of bactericidal activity: approximately 24 hours, supporting once-daily dosing; post-antibiotic effect (PAE) of 3-6 hours. |
| Molecular Weight | 1620.69 |
Adults: 6 mg/kg IV over 30-60 minutes every 24 hours. For deep-seated infections (e.g., endocarditis, osteomyelitis), consider 10 mg/kg IV every 24 hours.
| Dosage form | POWDER |
| Renal impairment | CrCl ≥30 mL/min: no adjustment; CrCl <30 mL/min: 6 mg/kg IV every 48 hours. For deep-seated infections in CrCl <30 mL/min, consider 10 mg/kg every 48 hours. Administer after hemodialysis on dialysis days. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Children 1-17 years: 6 mg/kg IV over 30-60 minutes every 24 hours (off-label for most indications; safety and efficacy not established for all uses). Infants and neonates: not recommended due to lack of data and potential for higher mortality in neonates. |
| Geriatric use | No specific dose adjustment based on age alone. Monitor renal function closely; use creatinine clearance to determine dosing interval as per renal adjustment guidelines. |
| 1st trimester | Limited human data; daptomycin crosses placenta in animals; use only if clearly needed. |
| 2nd trimester | Limited human data; animal studies show no evidence of harm; use only if clearly needed. |
| 3rd trimester | Limited human data; consider risk of ototoxicity in neonate if used near term; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for CUBICIN RF (CUBICIN RF).
| Placental transfer | Daptomycin crosses the placenta in animal studies; human data limited. |
| Breastfeeding | Daptomycin is excreted in human milk in low concentrations; caution advised, especially in neonates with immature renal function. |
| Lactation Rating |
■ FDA Black Box Warning
Eosinophilic pneumonia and anaphylaxis/hypersensitivity reactions have been reported. Daptomycin is not indicated for the treatment of pneumonia.
| Serious Effects |
Hypersensitivity to daptomycin
| Precautions | Eosinophilic pneumonia (monitor for cough, fever, dyspnea, pulmonary infiltrates), Peripheral neuropathy, Skeletal muscle effects: monitor CPK levels weekly due to risk of myopathy and rhabdomyolysis, Hypersensitivity reactions including anaphylaxis, Reduced efficacy in patients with moderate to severe renal impairment |
| Food/Dietary | No known food interactions. Take without regard to meals. Avoid alcohol during therapy due to potential hepatotoxicity. |
Loading safety data…
| L3 (Limited Data - Probably Compatible) |
| Teratogenic Risk | Cubicin RF (daptomycin) is classified as pregnancy category B. Animal studies have not demonstrated fetal risk, but there are no adequate and well-controlled studies in pregnant women. Daptomycin should be used during pregnancy only if clearly needed. First trimester: No known teratogenic effects; second and third trimesters: No known fetal harm, but limited human data. |
| Fetal Monitoring | Monitor for signs of hypersensitivity, peripheral neuropathy, and skeletal muscle toxicity (e.g., CPK levels). Also monitor for superinfection, Clostridioides difficile-associated diarrhea, and eosinophilic pneumonia. Fetal monitoring via ultrasound if prolonged use during pregnancy. |
| Fertility Effects | In animal studies, daptomycin did not impair fertility. There are no human studies on fertility effects. |
| Clinical Pearls |
| CUBICIN RF (daptomycin) is a once-daily lipopeptide antibiotic with rapid bactericidal activity against Gram-positive organisms including MRSA. Monitor CPK levels weekly due to risk of myopathy; discontinue if CPK >10x ULN or with symptoms. Avoid use in pneumonia due to inactivation by pulmonary surfactant. Dose adjustment required for CrCl <30 mL/min. Not effective for vancomycin-resistant Enterococcus faecium (VRE faecium) unless specifically tested. |
| Patient Advice | Take this medication exactly as prescribed by your healthcare provider. · Report any new muscle pain, weakness, or tenderness immediately. · Notify your doctor if you develop numbness, tingling, or skin changes in hands/feet. · Complete the full course of therapy even if you feel better. · Inform your doctor about all medications and supplements you take. · Contact your doctor if you experience shortness of breath, severe diarrhea, or allergic reactions. |